1NE Stock Overview
A clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Verrica Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.93 |
| 52 Week High | US$8.72 |
| 52 Week Low | US$0.64 |
| Beta | 1.46 |
| 11 Month Change | -35.52% |
| 3 Month Change | -64.21% |
| 1 Year Change | -71.63% |
| 33 Year Change | -90.36% |
| 5 Year Change | -93.35% |
| Change since IPO | -94.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1NE | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 16.2% | -1.2% | -0.02% |
| 1Y | -71.6% | -20.1% | 8.2% |
Return vs Industry: 1NE underperformed the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: 1NE underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 1NE volatility | |
|---|---|
| 1NE Average Weekly Movement | 23.1% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1NE's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1NE's weekly volatility has increased from 17% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 100 | Jayson Rieger | www.verrica.com |
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial.
Verrica Pharmaceuticals Inc. Fundamentals Summary
| 1NE fundamental statistics | |
|---|---|
| Market cap | €43.35m |
| Earnings (TTM) | -€81.62m |
| Revenue (TTM) | €8.84m |
4.9x
P/S Ratio-0.5x
P/E RatioIs 1NE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1NE income statement (TTM) | |
|---|---|
| Revenue | US$9.21m |
| Cost of Revenue | US$22.68m |
| Gross Profit | -US$13.47m |
| Other Expenses | US$71.52m |
| Earnings | -US$84.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.86 |
| Gross Margin | -146.28% |
| Net Profit Margin | -922.81% |
| Debt/Equity Ratio | -127.2% |
How did 1NE perform over the long term?
See historical performance and comparison